Workflow
CAR - T Therapy
icon
Search documents
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Prnewswire· 2025-06-30 12:31
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Proposed acquisition strengthens AbbVie's commitment to transforming the future of patient care with Capstan's innovative tLNP platform technologyNORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: AB ...
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
ZACKS· 2025-06-25 15:05
Key Takeaways CRSP is the first to market a CRISPR/Cas9 therapy, with Casgevy approved for SCD and TDT in multiple regions CRSP's pipeline spans ex vivo and in vivo therapies, including early success with CTX310. NTLA focuses on late-stage in vivo programs but faces setbacks, including a liver safety concern with nex-z.CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the f ...
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
Prnewswire· 2025-05-06 12:45
Core Insights - Actinium Pharmaceuticals is advancing Iomab-ACT, a targeted radiotherapy conditioning agent intended to replace traditional chemotherapy agents for CAR-T therapy, with initial clinical data expected in the second half of 2025 [1][2][3] - The Iomab-ACT trial aims to improve patient access and outcomes by reducing CAR-T related toxicities such as ICANS and CRS, which are significant barriers for patients [2][3] - The CAR-T therapy market generated over $4 billion in sales in 2024 and is projected to reach $12 billion by 2030, indicating a substantial market opportunity for Iomab-ACT [1][5] Company Developments - The first patient has been enrolled in the Iomab-ACT trial at the University of Texas Southwestern Medical Center, marking a significant step in the development of this innovative therapy [1][2] - Iomab-ACT targets CD45, selectively depleting immune cells associated with CAR-T toxicities while sparing essential blood components, which could lead to better patient outcomes [2][3] - Initial clinical results from a pilot study showed no patients developed ICANS and minimal CRS, supporting the advancement of Iomab-ACT into commercial trials [2][3] Market Opportunity - The addressable market for Iomab-ACT aligns with the approximately 150,000 patients annually who require conditioning for CAR-T therapies, suggesting a potential blockbuster revenue opportunity if clinical benefits are demonstrated [5] - The pipeline of CAR-T therapies is rapidly expanding, with the patient population expected to nearly double by 2030, further enhancing the market potential for Iomab-ACT [5]
Legend Biotech(LEGN) - 2024 Q4 - Earnings Call Transcript
2025-03-11 16:06
Legend Biotech Corporation (NASDAQ:LEGN) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim CFO Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Jon Miller - Evercore Hang Hu - Barclays Yaron Werber - TD Cowen Jessica Fye - JPMorgan Ziyi Chen - Goldman Sachs Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Sta ...